UNITED THERAPEUTICS Corp Form 8-K July 28, 2011

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

## FORM 8-K

#### **CURRENT REPORT**

Pursuant to Section 13 or 15 (d) of the

Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 28, 2011

# **United Therapeutics Corporation**

(Exact Name of Registrant as Specified in Charter)

**Delaware** (State or Other Jurisdiction of Incorporation)

**000-26301** (Commission File Number)

**52-1984749** (I.R.S. Employer Identification Number)

1040 Spring Street Silver Spring, MD (Address of Principal Executive Offices)

**20910** (Zip Code)

Registrant s telephone number, including area code: (301) 608-9292

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under	any of
the following provisions:	

o	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
0	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 2.02. Results of Operations and Financial Condition.
On July 28, 2011, United Therapeutics Corporation issued a press release setting forth its earnings for the quarter ended June 30, 2011.
A copy of the press release is attached hereto as Exhibit 99.1.
Item 9.01. Exhibits
This information shall not be deemed to be filed for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933 as amended, except as shall be expressly set forth by specific reference in such filing.
(d) Exhibits
Exhibit No. Description of Exhibit
99.1 Press release dated July 28, 2011
2

#### **SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

UNITED THERAPEUTICS CORPORATION

Dated: July 28, 2011 By: /s/ Paul A. Mahon

Name: Paul A. Mahon Title: General Counsel

3

#### **Exhibit Index**

Exhibit No. Description of Exhibit

99.1 Press release dated July 28, 2011

4